Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis
Primary Purpose
Osteo Arthritis Knee
Status
Completed
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
allogenic lyophilized growth factors
Sponsored by
About this trial
This is an interventional treatment trial for Osteo Arthritis Knee focused on measuring osteoarthritis, allogenic platelet rich plasma, lyophilization, growth factors
Eligibility Criteria
Inclusion Criteria
- Clinical and radiographic diagnosis of primary knee osteoarthritis
- Patients must be symptomatic
Exclusion Criteria:
- Patients with secondary knee osteoarthritis
- previous intra-articular steroid, or hyaluronic knee injection in last year
- Patients with other disabling lower limb osteoarthropathy or myopathy
Sites / Locations
- rheumatology and clinical immunology unit of internal medicine department of Kasr Al-ainy Hospital, Cairo University
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Allogenic lyophilized growth factors
Standard of care
Arm Description
Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
The patients were kept on their traditional medications without any intervention
Outcomes
Primary Outcome Measures
Change from Baseline WOMAC scores at 6 months
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores consist of 24 questions in 3 sections regarding; five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). A sum of the scores for all three sub-scales gives a total WOMAC score. The higher scores mean a worse outcome.
Change from Baseline structural outcomes scores at 6 months
Knee ultrasonography assessment of effusion, femoral cartilage, anterior horn medial meniscus, synovial hypertrophy
Secondary Outcome Measures
post injection complications of the intervention treatment
The patients of the intervention group were asked if they experienced any adverse events following the injection, with special concern on:
Post-injection pain: Both the duration and intensity were documented. The pain intensity was measured by 0-10 visual analogue scale (VAS).
General symptoms or signs related to infection and allergy such as fever, chills, pruritus, dyspnea, urticaria, or rash.
Erythema, swelling, or abnormal discharge from the site of injection.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04331327
Brief Title
Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis
Official Title
Clinical and Ultrasonographic Assessment of Effectiveness of Intra-articular Knee Injection Using Platelet Derived Lyophilized Growth Factors in Egyptian Patients With Symptomatic Primary Knee Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
May 1, 2017 (Actual)
Primary Completion Date
April 28, 2018 (Actual)
Study Completion Date
April 28, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Rasmia Elgohary
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
the study was conducted on 31-patients with symptomatic primary knee osteoarthritis. The patients were randomized into intervention and control groups. The control group was kept on their medications without intervention. The intervention group received two doses of allogenic lyophilized growth factors (L-GFs); at baseline and after 2 months.
Detailed Description
the study included 31 patients with symptomatic primary knee osteoarthritis (KOA) The study group was randomized into an intervention group and a control one. The control group patients were kept on their traditional medications without any intervention, while intervention group patients were instructed to stop using non-steroidal anti-inflammatory drugs (NSAID) at least 1 week before the assessment and throughout the study. All participants were subjected to baseline clinical, radiographic, and ultrasonography assessment. Follow up assessments was conducted after 6 months.
Patients of the intervention group received two doses of intra-articular knee injections of allogenic lyophilized growth factors (L-GFs); one dose at the baseline and the other was after 2 months.
Lyophilized GFs were prepared at the Cairo Medical Centre Blood Bank from allogenic platelet rich plasma to according a previously published patented method.
Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
The injection was done under complete guidance of ultrasonography through lateral supra-patellar short axis in-plane approach under sterile aseptic conditions. After injection, local ice application and oral paracetamol were allowed if the patient felt pain. NSAIDs were completely avoided as they may inhibit the desired post-injection inflammatory process. Patients were encouraged to restrict vigorous knee activities for 48 hours.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteo Arthritis Knee
Keywords
osteoarthritis, allogenic platelet rich plasma, lyophilization, growth factors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Allogenic lyophilized growth factors
Arm Type
Active Comparator
Arm Description
Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
Arm Title
Standard of care
Arm Type
No Intervention
Arm Description
The patients were kept on their traditional medications without any intervention
Intervention Type
Drug
Intervention Name(s)
allogenic lyophilized growth factors
Intervention Description
Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
Primary Outcome Measure Information:
Title
Change from Baseline WOMAC scores at 6 months
Description
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores consist of 24 questions in 3 sections regarding; five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). A sum of the scores for all three sub-scales gives a total WOMAC score. The higher scores mean a worse outcome.
Time Frame
At baseline and after 6 months.
Title
Change from Baseline structural outcomes scores at 6 months
Description
Knee ultrasonography assessment of effusion, femoral cartilage, anterior horn medial meniscus, synovial hypertrophy
Time Frame
At baseline and after 6 months.
Secondary Outcome Measure Information:
Title
post injection complications of the intervention treatment
Description
The patients of the intervention group were asked if they experienced any adverse events following the injection, with special concern on:
Post-injection pain: Both the duration and intensity were documented. The pain intensity was measured by 0-10 visual analogue scale (VAS).
General symptoms or signs related to infection and allergy such as fever, chills, pruritus, dyspnea, urticaria, or rash.
Erythema, swelling, or abnormal discharge from the site of injection.
Time Frame
at each time following the injection
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Clinical and radiographic diagnosis of primary knee osteoarthritis
Patients must be symptomatic
Exclusion Criteria:
Patients with secondary knee osteoarthritis
previous intra-articular steroid, or hyaluronic knee injection in last year
Patients with other disabling lower limb osteoarthropathy or myopathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kamel Gado, MD
Organizational Affiliation
Kasr Alainy School of Medicine, Cairo University
Official's Role
Principal Investigator
Facility Information:
Facility Name
rheumatology and clinical immunology unit of internal medicine department of Kasr Al-ainy Hospital, Cairo University
City
Cairo
ZIP/Postal Code
11562
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
study protocol and statistical analysis plan
IPD Sharing Time Frame
after publication
Citations:
PubMed Identifier
33754800
Citation
El-Gohary R, Diab A, El-Gendy H, Fahmy H, Gado KH. Using intra-articular allogenic lyophilized growth factors in primary knee osteoarthritis: a randomized pilot study. Regen Med. 2021 Feb;16(2):113-115. doi: 10.2217/rme-2020-0104. Epub 2021 Mar 23.
Results Reference
derived
Links:
URL
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018091713
Description
A patent method describing the preparation of lyophilized growth factors from allogenic platelet rich plasma
Learn more about this trial
Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis
We'll reach out to this number within 24 hrs